All In Biotech

Drug Trial Radar · NCT07288216

Transition to KPL-387 Monotherapy Dosing & Administration Study

A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 25, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
Collaborators
Kiniksa Pharmaceuticals, GmbH
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.

Conditions

  • Recurrent Pericarditis
  • Heart Diseases
  • Pericarditis

Interventions

  • KPL-387Drug

    administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Posology: Proportion of participants free from Pericarditis Recurrence by Week 16Time frame: From baseline up to Week 16
  2. Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE.Time frame: Up to 24 Months

Locations

48 sites in 10 countries. Site status is shown where the registry gives one.

  • Investigational Site 031

    Phoenix, Arizona · Recruiting

  • Investigational Site 045

    La Jolla, California · Recruiting

  • Investigational Site 014

    Los Angeles, California · Recruiting

  • Investigational Site 002

    Santa Monica, California · Recruiting

  • Investigational Site 046

    Washington D.C., District of Columbia · Recruiting

  • Investigational Site 039

    Jacksonville, Florida · Recruiting

  • Investigational Site 013

    Chicago, Illinois · Recruiting

  • Investigational Site 025

    Baltimore, Maryland · Recruiting

  • Investigational Site 043

    Boston, Massachusetts · Recruiting

  • Investigational Site 028

    Rochester, Minnesota · Recruiting

  • Investigational Site 042

    St Louis, Missouri · Recruiting

  • Investigational Site 011

    New York, New York · Recruiting

  • Investigational Site 003

    New York, New York · Recruiting

  • Investigational Site 009

    Cincinnati, Ohio · Recruiting

  • Investigational Site 040

    Cleveland, Ohio · Recruiting

  • Investigational Site 005

    Austin, Texas · Recruiting

  • Investigational Site 047

    Dallas, Texas · Recruiting

  • Investigational Site 006

    Houston, Texas · Recruiting

  • Investigational Site 004

    Charlottesville, Virginia · Recruiting

  • Investigational Site 001

    Norfolk, Virginia · Recruiting

  • Investigational Site 008

    Richmond, Virginia · Recruiting

  • Investigational Site 010

    Ottawa, Ontario, Canada · Recruiting

  • Investigational Site 027

    Paris, France · Recruiting

  • Investigational Site 026

    Poitiers, France · Recruiting

  • Investigational Site 032

    Toulouse, France · Recruiting

  • Investigational Site 038

    Toulouse, France · Recruiting

  • Investigational Site 041

    Dresden, Germany · Recruiting

  • Investigational Site 035

    Athens, Greece · Recruiting

  • Investigational Site 023

    Nea Ionia, Greece · Recruiting

  • Investigational Site 024

    Voula, Greece · Recruiting

  • Investigational Site 044

    Florence, Italy · Recruiting

  • Investigational Site 034

    Genoa, Italy · Recruiting

  • Investigational Site 021

    Milan, Italy · Recruiting

  • Investigational Site 036

    Padua, Italy · Recruiting

  • Investigational Site 033

    Udine, Italy · Recruiting

  • Investigational Site 037

    Varese, Italy · Recruiting

  • Investigational Site 048

    Warsaw, Poland · Recruiting

  • Investigational Site 020

    Warsaw, Poland · Recruiting

  • Investigational Site 030

    Belgrade, Serbia · Recruiting

  • Investigational Site 029

    Belgrade, Serbia · Recruiting

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.